text:
2013 will be my first Coachella experience and all I want is for at least one G.O.O.D. music artist to perform.
.....And if Kanye headlined again? DAMN.
2013 will be my first Coachella experience and all I want is for at least one G.O.O.D. music artist to perform.
.....And if Kanye headlined again? DAMN.
Kanye is your definition of good?
Ain't nobody fresher...
fuckin' with the lights on
Common would be nice.
Bout time Kid Cudi showed up on the fields. And a Mos Def (Excuse me Yasiin Bey) set would be appreciated
My 4th Annual Coachelectro (Coachella 2015) Mix
Featuring 80 Acts Playing The Fest This Year In Just An Hour + Free Download
Anything to bring 2 Chainz to the Polo Fields
I'm way too black to burn from sunrays.
fuckin' with the lights on
Common would surpass "nice".
If everyone signed to G.O.O.D. actually performs then fuck yes
Saw G.O.O.D music's set at Made In America. It was so dope. I could see Cudi being on the lineup, especially with a new album coming out. Big Sean would be dope too!
Saw Cudi at Red Rocks live and the show was pretty damn good.
I would consider myself a huge Kid Cudi fan & I would say at one point in time this was true. Early in his career he just wasn't that good and if you saw him at Audiotistic as many board members have then let me tell you that was the worst he has ever been.
Now since he has added a band, visuals and gotten sober he is actually an amazing performer (granted you like his music). But if you think he is garbage then....yeah you aren't gonna like him live.
Last edited by WhyTheLongFace; 10-12-2012 at 01:29 PM.
Having G.O.O.D music for this upcoming Coachella lineup would be SO awesome
its hilarious how the whole world knows kanye absolutely destroyed that performance in '11 and yet the fucking clown ass edm meatheads on this board try and act like he was a bad headliner
ban all EDM from Coachella, that would be nice.
Also saw Kudi "warm up" for Empire of the Sun at Red Rocks, and to say it was "sublime" would be a gross understatement. Kid Cudi puts on a phenomenal live show, which pretty much becomes a singalong for about half his songs. He is a consummate showman, and I would welcome his addition to Coachella 2013.
What does G.O.O.D stand for? Last time i checked coachella has some pretty good artists every year!
Everyone's a Photographer
Kanye's performance in 2011 was THE BEST performance ive seen in my life. And i've seen a ton of em. Dude was on fire! Sadly, he probably won't be headlining anytime soon
If Common were on, I'm sure he'd bring on his boy Kanye for a song or two
http://showscoop.com - Tour Reviews, Concert Reviews, and rate how bands perform live.
I wan't Mumford and sons to headline!!! And also Ben Howard :-D


text: The Great Kate: Jez & The Amazing, Technicolor DreambloggerAnna Holmes9/01/09 9:20amFiled to: Welcome WagonKate HardingShapely proseSalonBody acceptance60EditPromoteShare to KinjaToggle Conversation toolsGo to permalinkAnother day, another amazing guest-blogger. Please welcome writer Kate Harding, proprietress of body-acceptance blog Shapely Prose, and author of/contributor to numerous books, including Lessons from the Fat-o-Sphere: Quit Dieting and Declare a Truce With Your Body and Yes Means Yes.Kate is also a regular contributor to the Broadsheet section of Salon. When she is not knocking Jez editors' socks off and inspiring millions of readers with her intelligent, humorous, and decisive writing about all manner of issues pertaining to women and body image, she is chilling out at home in Chicago with her husband and two dogs. Please give her a warm welcome.AdvertisementAdvertisementShapely Prose [Official Site] Kate Harding Writes Stuff [Official Site] Kate Harding's Twitter [Twitter] Lessons From The Fat-O-Sphere: Quit Dieting And Declare A Truce Yes Means Yes: Visions Of Female Sexual Power And A World Without Rape [Powell's]Reply60 repliesLeave a reply

subset: commoncrawl


text: SC adding Vencill as boys assistant coach June 2, 2013 CHARLESTON, W.Va. -- John Vencill, a former longtime coach at Capital, has been added to the boys basketball staff at South Charleston.He recorded 224 wins as head boys basketball coach at Capital and one of its predecessors, Charleston High, which closed in 1989. Vencill, 68, also served as an assistant coach at Capital in boys and girls basketball and football and at Charleston High in football and boys basketball. Vencill, who joins the staff of SC coach Vic Herbert, said it's been about 10 years since he coached basketball. He still teaches calculus and math courses at Capital."I never really gave it a second thought,'' Vencill said of returning to the bench. "Coach Herbert called me one day and said, 'I'd like to pick your brain.' I'd coached against him when he was at Logan, so I thought it was about that. I realized about five minutes into our talk, it was more than that. "I prayed about it and I thought about it and I said, 'I like kids,' and it's a chance for me to get back into it and see how it goes.''


text:
Did DoJ approve "a different approach" to gunwalking in 2010?
posted at 9:15 am on February 2, 2012 by Ed Morrissey
Eric Holder goes back up the Hill today to tell Congress that he doesn't have to share his e-mails with anyone, but that may be a little too late. A new report from Rep. Darrell Issa and Senator Charles Grassley allege that Holder deputy Lanny Breuer gave the ATF a green light on a "different approach" to interdicting weapons going across the border in 2010, and then failed to follow up — at best — on Operation Fast and Furious:
The memo, sent to Republican members of the Oversight Committee, was based upon interviews, documents and emails involving key players of the operation run by the Bureau of Alcohol, Tobacco, Firearms and Explosives. The operation allowed some 2,000 weapons cross the border into Mexico and into the hands of cartel members. …
The memo claims there was coordination between the Justice Department in Washington and the ATF in the early stages of the operation.
Emails released show that Kenneth Melson, former Acting Director of the ATF contacted Assistant Attorney General Lanny Breuer and told him that his organization wanted to take a "different approach" to seizing guns going to Mexico.
Breuer responded that it was a "terrific idea" and the Department assigned a prosecutor from its Criminal Division to work with the ATF in early 2010.
Republicans say attorney Joe Cooley attended key briefings on the program and should have alerted the Justice Department to what was going on. The memo also alleges that there was a lack of management by both the ATF and Justice Department with the use of federal wiretaps.
According to the memo, "Both Justice Department and ATF leaders in Washington, D.C. claimed they were unaware of the gunwalking that occurred during Fast and Furious, yet both could have and should have reviewed the Wiretap Affidavits."
So what exactly was "a terrific idea"? Until now, Breuer and Holder have both claimed that they didn't know that the ATF was doing anything differently than their traditional interdiction strategies. This "terrific idea" seems to be closely related to Operation Fast and Furious, and the only innovation in that effort was letting the guns go across the border without coordinating with the Mexican government — the very issue Congress seeks to expose.
You know what would clear this up? Access to Holder's e-mails and other work products, but Holder will claim today that those are somehow privileged — an interesting assertion. Holder won't quite claim executive privilege but instead will try to parallel it, claiming in his prepared testimony (via Jim Geraghty):
Prior administrations have recognized that robust internal communications would be chilled, and the Executive Branch's ability to respond to oversight requests thereby impeded, if our internal communications concerning our responses to congressional oversight were disclosed to Congress. … The appropriate functioning of the separation of powers requires that Executive Branch officials have the ability to communicate confidentially as they discuss how to respond to inquiries from Congress. …
Such candid internal deliberations are necessary to preserve the independence, integrity, and effectiveness of the Department's law enforcement activities and would be chilled by disclosure to Congress of such materials. Just as we have worked to accommodate the Committee's legitimate oversight needs, I trust that the Committee will equally recognize the Executive Branch's constitutional interests and will work with us to avoid further conflict on this matter.
Executive privilege does not flow downward from the President to the entire executive branch, however. The President has (a very limited) recourse to executive privilege not because he has confidential consultations, but because the people elected him separately to run the executive branch. It does not extend to even others in the White House unless the communications sought involve the President directly. It certainly doesn't apply to leadership of agencies within the executive branch, who are explicitly accountable to Congress and whose agencies exist under a blend of both executive and legislative prerogatives. The only way executive privilege could be claimed would be to assert that the President was involved in these discussions, which I assume would be the last thing Obama wants this year.
Eric Holder has no executive privilege, and the Senate might have to start considering how to remove him if he refuses to cooperate with legitimate oversight into an operation that has killed hundreds of Mexicans and a Border Patrol agent with weapons the ATF deliberately allowed to fall into the hands of the drug cartels.
Geraghty's conclusion sums it up well:
Thus, the administration that took military action in Libya without any authorization from force from Congress, that appointed czars with policymaking authority without Congressional confirmation, and that made 'recess' appointments while Congress was not in recess is invoking executive privilege to cover how the Department of Justice reacted when Congress began asking about a gun-trafficking operation that got U.S. law enforcement officers murdered by Mexican drug cartels.
All from a president who railed against a runaway imperial presidency when George W. Bush sat in the office he currently occupies.
Related Posts:
Breaking on Hot Air
EU chief: We might try breaking up the US if Trump doesn't stop dissing us
LA Times: Felony charges against producers of undercover Planned Parenthood videos go too far
- Eric Holder To Become A Campaign Issue? | hogewash
- Boehner puts on brakes of Gunwalker investigation | Congressman Tom Tancredo
- Family in jail for Eric Holder's crimes. | Grumpy Opinions
- Judiciary Chairman Unleashes on Holder for 'Partisan' Ignorance of Constitution | Congressman Tom Tancredo
- The Gunwalker Scandal: Overview and Timeline
- The Gunwalker Scandal: Overview and Timeline | Bobusnr
- The Gunwalker Scandal: Overview and Timeline, Part 2


text:
Search Results
Use the back button to select a different record.
Integration at Gainesville Elementary (Hopkinsville, KY)
Start Year
: 1965
When 27 year old Ronald I. Johnson became principal of the African American Gainesville Elementary School in 1965, it was thought to be the first integration of school administrative personnel in Hopkinsville, KY. Johnson had been a basketball coach for five years prior to becoming principal. For more see "White basketball coach heads Ky. Negro school," Jet, vol. 28, issue 15 (07/22/1965), p. 55. See also entries for African American Schools in the NKAA Database.
Education and Educators,
Grade Schools & High Schools in Kentucky
Geographic Region: Hopkinsville, Christian County, Kentucky


text:
Silva Map Measure 701
Retailers' Descriptions
Here's what other sites are saying:
Gives you accurate direct readings in miles and kilometers, for 1:24,000, 1:62,500, and 1:250,000 maps and inch and centimeter dials for maps of unknown scale. Revolution counter and reset wheel. Size: 1 7/8 in. x 4 5/8 in. Wt. 1 oz.
- Campmor
Graduation in miles for 1:24,000, 1:62,500, 1:250,000 scale U.S.G.S. maps and in kilometers for 1:25,000, 1:50,000, 1:100,000 scale maps allows ultimate precision and accuracy. Also provides inch and centimeter graduations for maps of other scales. Revolution counter, reset wheel and folding magnifier add even more precision. Includes vinyl storage pouch.
- Ramsey Outdoor
Silva's Map Measure 701 offers precision, durability and utility, with several scales for numerous map types.
- FogDog Sports
Silva Map Measure 701
$14.95 - $19.99
The Map Measure 701 has been discontinued.
previously retailed for:$14.95 - $19.99
The Silva Map Measure 701 is not available from the stores we monitor. It was last seen October 15, 2011 at Campmor.
If you're looking for a new handheld compass, check out the best reviewed current models.


text:
The final vote had been taken, the ink dried, and the final documents dropped in the mail.
But now, after spending months trying to merge two of Lucas County's oldest mental health and substance abuse counseling services, authorities are trying to untangle the marriage.
The problem was not with each other, say directors of both agencies - Connecting Point, which works with some of the area's most troubled and mentally ill youth, and the Zepf Center, which provides the same services but to adults.
It was that the financing fell through at the last minute.
"It came down the bank would not authorize a sufficient line of credit to assure the cash flow needs," said Frank Ayers, interim director of Zepf.
Mr. Ayers was supposed to retire July 1, the first day of the merger. And even throughout that day, it appeared that every-thing was on schedule.
The boards of directors had taken their final votes, several management positions had been eliminated or realigned, and the merger papers had been sent to the Ohio Secretary of State's Office, said Jeff Deckebach, director of Connecting Point.
Zepf was to become a division of Connecting Point.
But as the Independence Day holiday week began, the final proposal from the bank - neither Mr. Ayers nor Mr. Deckebach would identify which bank - came through. And after meeting with the bank after the holiday, it was obvious the deal was falling through.
Both men said they were disappointed, and the agencies have worked together to undo the merger. And both said they might revisit the proposal at another time.


text:
- 2721 Hwy 52 Eldon, MO 65026
- 3 beds
- 5 baths
- 5,049 sq. ft.
- Single-Family
Listing Information Copyright 2017 Multiple Listing Service of Lake of the Ozarks Board of REALTORS® Inc.
The information being provided is for consumers' personal, non-commercial use and will not be used for any purpose other than to identify prospective properties consumers may be interested in purchasing. The data relating to real estate for sale on this website comes in part courtesy of the Broker Reciprocity Internet Data Exchange Program of the Multiple Listing Service of Lake of the Ozarks Board of REALTORS® Inc. Real estate listings held by brokerage firms other than RE/MAX Kansas-Missouri are governed by MLS Rules and Regulations and detailed information about them includes the nameof the listing companies.


text:
PAY FOR 1 WEBSITE AND GET ACCESS to 14 PAYSITES !!! |
I'd do anything just to let a horse cum inside my mouth or my pussy... or to have a horse piss on me, that would feel so good.
A Beautiful Girl, That Not Only Sucks Off The Huge, Erect, Horse Cock, Getting Bathed In Warm, Fresh, Cum, But Takes The Tremendous Meat, In Her Tight, Juicy, Pussy, As Well!.....What MORE Can You Ask For!.....^_^.....BRAVO!......FIVE STARS!!! *****


text:
Johnny Manziel mania is at its full peak right now and I must say, it may have outgrown Tebow mania in one season.
Manziel has folks getting tattoos, moms making music videos for him, and the newest trend, grown men getting pictures of Manziel shaved into their hair.
USA Today is reporting that a Texas A&M fan had a San Antonio barber shave and paint a photo of Manziel into the back of his head.


text:
TeachNext is a digital learning ecosystem which makes the end-to-end process of teaching and learning easy and more engaging. At the core of TeachNext is a rich multimedia based, pedagogically appropriate content mapped to school curricula.
Apart from digital classroom hardware and content, the TeachNext ecosystem includes various features that make everything from planning a class to evaluating students very effective.
With more than 6500 partner schools, TeachNext is India's leading and most trusted digital classroom ecosystem.


text:
Lou Reed: 'Working with him was joyous and delightful'
27 October 2013 Last updated at 19:57 GMT
A singer who worked with the legendary rock star Lou Reed has described the experience as "joyous and delightful".
Casey Synge was part of the British backing vocal group Thunderthighs, which sang on his seminal hit, Walk on the Wild Side.
Reed, whose other hits included Perfect Day, has died at the age of 71.


text:
Vulnerability Assessment & Network Security Forums |
If through a vulnerability assessment, a network security issue is detected for the vulnerability below, applying the appropriate security patches in a timely matter is very important. If you have detected that your system has already been compromised, following CERT's Network Security recovery document will assist with recommended steps for system recovery. Home >> Browse Vulnerability Assessment Database >> Fedora Local Security Checks >> Fedora Core 3 2005-369: gaim Vulnerability Assessment Details
Fedora Core 3 2005-369: gaim |
Check for the version of the gaim package Detailed Explanation for this Vulnerability Assessment The remote host is missing the patch for the advisory FEDORA-2005-369 (gaim). Gaim permits you to talk to anyone using a variety of messaging protocols, including AIM (Oscar and TOC), ICQ, IRC, Yahoo!, MSN Messenger, Jabber, Gadu-Gadu, Napster, and Zephyr. These protocols are implemented using a modular, easy to use design. To use a protocol, just add an account using the account editor. Gaim supports many common features of other clients, as well as many unique features, such as perl scripting and C tests. Gaim is NOT affiliated with or endorsed by America Online, Inc., Microsoft Corporation, or Yahoo! Inc. or other messaging service providers. Update Information: Many bug fixes and two important security fixes. Solution : http://www.fedoranews.org/blog/index.php?p=662 Network Security Threat Level: High Networks Security ID: Vulnerability Assessment Copyright: This script is Copyright (C) 2005 Tenable Network Security |
Cables, Connectors |
No Discussions have been posted on this vulnerability. |


text:
Event ContactsPaid membership required to see this information
Event WebsitePaid membership required to see this information
Event Description
Event Overview:
Join your colleagues from across the U.S. and over 50 other countries for the psychiatry event of the year!
The dynamic nature of mental health means you need to stay on top of advances to better serve your patients. What better way to do this than to learn from the world\'s largest and longest-serving psychiatric organization? The voice and conscience of modern psychiatry, the American Psychiatric Association currently represents a growing membership of 36,000 psychiatrists globally. Our member physicians work together to ensure humane care and effective treatment for all persons with mental disorders.
Attend this year\'s Annual Meeting to gain insight into the tools and in-depth knowledge you need to improve your patient care. The Scientific Program will feature a variety of innovative sessions and inspiring Courses with tracks focusing on changing the practice and perception of psychiatry. The Annual Meeting is not just a meeting, it is a complete experience of continual growth engaging you to learn from renowned experts, earn credits, build peer relationships, discover ground-breaking technology, and understand new therapies and treatment options.
Attendee Information:
Top 5 Reasons You Should Attend
Earn your annual state licensure CME credit at one meeting.
Discover cutting-edge science and new therapies.
Learn from renowned thought leaders in the areas of health policy and ethics.
Reconnect with your peers and expand your professional network.
Explore the exhibit hall for innovative treatment options and new technologies.
Who Should Attend?
Over five days those who will shape the future of psychiatry will come together under one roof. The Annual Meeting is designed for all mental health professionals and advocates including practicing, administrative, and consultative psychiatrists, researcher and educators of psychiatry, residents, and students. Whether you work in a private hospital, state mental health facility, or private practice APA\'s Annual Meeting has something to offer you.
Exhibitor Information:
The American Psychiatric Association (APA) Annual Meeting offers you access to the largest audience of psychiatrists, psychologists, social workers, psychiatric nurses, occupational therapists, and behavioral healthcare professionals.
Does your product or service transform psychiatry practice or help to reform health care delivery? Showcase your technology, education, research, job opportunities, diagnostic tools, and treatment options at this meeting.
As an exhibitor at the APA Annual Meeting, this is the perfect opportunity for you to:
• Generate new sales leads
• Interact with psychiatrists from the U.S. and around the world
• Build visibility for your company
• Introduce new products and service to attendees
• Advertise to a wide range of attendees
About APA:
The American Psychiatric Association is the world's largest psychiatric organization. It is a medical specialty society representing growing membership of more than 36,000 psychiatrists.
Its member physicians work together to ensure humane care and effective treatment for all persons with mental disorders, including intellectual disabilities and substance use disorders. APA is the voice and conscience of modern psychiatry.
If the 2016 APA Annual Meeting - American Psychiatric Association is important to your business, act now and make the appropriate connections. See the contact information below.
Event Details
Conference/Event Dates: | 05/14/2016 - 05/18/2016 |
Conference/Event Hours: | Sat, 8am-5pm; Sun, 8am-4pm; Mon & Tues, 8am-5pm; Wed, 9am-5pm |
Expo/Exhibit Dates: | 05/14/2016 - 05/17/2016 |
Expo/Exhibit Hours: | Sun, 9am-4pm; Mon, Tues, Wed, 10am-4pm |
Classification: | B2B |
Primary Industry: | Mental Health / Psychiatry / Psychology / Counseling |
Other Industries: | Associations, Mental Health / Psychiatry / Psychology / Counseling, Professional Healthcare |
Estimated Attendance: | 13,000 |
Previous Attendance: | 10,821 |
Cost to Attend: | http://www.psychiatry.org/psychiatrists/meetings/annual-meeting/regist... |
Audience: | Psychiatrists & Psychiatric Professionals |
Notes: | Attendees' Disciplines: 6,513 Psychiatrist 991 Resident 723 Other 644 No Response 396 Other Mental Health Professional 393 Student 141 Other Physician 52 Mental Health Advocate |
Venue: | Georgia World Congress Center |
Venue Phone: | (404) 223-4000 |
Venue Type: | Indoor - Convention Center |
Official Conference Hotel: | Hotel Information: |
Conference Hotel URL: | http://www.psychiatry.org/psychiatrists/meetings/annual-meeting/housin... |
Number of Exhibitors: | 200+ Booths |
Event Square Footage: | 275,000 (Past Event) |
Exhibit Floorplan PDF: | Download Exhibit Floorplan PDF |
Show Owner: | American Psychiatric Association (APA) |
Show Manager: | APA |
Exhibitor Prospectus: | Click Here |
Sponsorship: | Yes |
Booth Details
Booth Size | Booth Cost | Available Amenities | ||||
10' x 10' Inline Booth | $3,200 | Electricity: | Yes | - Unknown Price | ||
10' x 10' Corner Booth | $3,300 | Water: | n/a | |||
Island Booths | $38 per sq. ft. | Generator: | n/a | |||
Marketing Vehicles Allowed: | Yes | |||||
Other Booth Sizes Available: n/a |
Advance NetworkingHow do I show up here?
Personal NotesAdd a note here, it is only visible by you.
Event Exhibitors
2015 Exhibitors:
45th EABCT Congress, ISAS International Seminars
ACADIA Pharmaceuticals
Actavis Pharma Inc.
ACUTE Center for Eating Disorders at Denver Health
Alkermes, Inc.
Alkermes, Inc.
Allina Health
American Academy of Addiction Psychiatry
American Board of Psychiatry and Neurology, Inc.
American College of Psychiatrists
American Physician Institute for Advanced Professional Studies
American Professional Agency, Inc.
Armor Correctional Health Services, Inc.
Association of Gay and Lesbian Psychiatrists
Assurex Health
AstraZeneca Pharmaceuticals
Aurora Health Care
Austen Riggs Center
Avanir Pharmaceuticals, Inc., Medical Affairs
bp Magazine and esperanza
Brain & Behavior Research Foundation/NARSAD Artworks
Brainsway Ltd.
Brazilian Association of Psychiatry
Brookhaven Retreat
California Correctional Health Care Services (CCHCS)
Cambridge University Press/Neuroscience Education Institute
Canadian ADHD Resource Alliance (CADDRA)
Cannon Design
Center for Eating Disorders at Sheppard Pratt (The)
CFG Health Network
Clinical Psychiatry News
Community Health Systems
Compulink Business Systems, Inc.
CooperRiis Healing Community
Corizon Health
Current Psychiatry
Cyber Relax/ACIGI Relaxation
Department of Health and Wellness
Diamond Healthcare Recruitment Division
DR Wanted
Eating Recovery Center
Electromedical Products International, Inc.
Elsevier, Inc.
European College of Neuropsychopharmacology (ECNP)
Evoke Neuroscience
FOCUS: The Journal of Lifelong Learning in Psychiatry
FORUM Pharmaceuticals, Inc.
Fraser Health
GenCAN (Gen-Clozapine Access Network)
Global Medical Staffing
Group Health Physicians
Guilford Publications
Harrington Healthcare
Hogrefe Publishing Corp.
Homewood Health
Horizon Health
Hospital Corporation of America (HCA)
HSHS Medical Group, Inc.
Hunt Psychiatric Innovations Inc.
Infinite Trading, Inc.
Infinite Trading, Inc.
Ingenuity Health
Intermountain Healthcare
International Congress on Dual Disorders and Dual Pathology
International Medical Recruitment
International Neuropsychiatric Association
IPC Healthcare
Jackson & Coker
JAMA Network (The)
Janssen Pharmaceuticals, Inc.
Johns Hopkins Healthcare Solutions
Kaiser Permanente, The Permanente Medical Group, Inc.
Lancet Psychiatry (The)
Locum Leaders
Luminello Inc.
MagVenture A/S
Magventure, Inc.
Maxim Physician Resources
Mayo Clinic
McLean Hospital
MECTA Corporation
Medical Search
Medicus Healthcare Solutions
Medley Pharmaceutical Ltd.
Menninger Clinic
Mental Health Center of Denver
Merck & Co.
Metabolic Maintenance
MHM Services, Inc.
MHS, Inc.
Millennium Health
Ministry Health Care
Multidisciplinary Association for Psychedelic Studies (MAPS)
National Institute on Alcohol Abuse and Alcoholism
Neuronetics, Inc.
New York Times (The)
New York-Presbyterian Hospital
Nexalin Technology, Inc.
Northern Light Technologies
Oregon Health & Science University, Department of Psychiatry
Oregon Health & Science University-Unity Hospital
Oregon State Hospital
Otsuka America Pharmaceutical, Inc.
Oxford University Press
Pacific Grove Hospital/Univ. of California at Riverside
Parental Alienation Awareness Organization
Pfizer Canada
Physicians for a National Health Program
Providence Health & Services
Psychiatric Times
Psychiatry Section, Christian Medical & Dental Associations
QTC Management
Quotient - ADHD System by Pearson
Rapid Psychler Press
Reckitt Benckiser Pharmaceuticals
Reflections at Dominion Hospital
Rhino Medical Services
Rogers Memorial Hospital
Routledge Journals
Routledge/CRC Press
Royal College of Psychiatrists
Rutgers Center of Alcohol Studies
Rx Concepts, LLC
SAGE/MD Conference Express
Scatterlings Conference and Events
Sheppard Pratt Health System
Shire U.S., Inc.
Somatics LLC
Sooma Oy
Spartanburg Regional Healthcare System
Springer Science+Business Media
Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc.
Sunrise Springs Integrative Wellness Resort
Takeda Pharmaceuticals U.S.A., Inc./Lundbeck
Teva Select Brands
Thought Technology
Thunder Bay Regional HSC/St. Joseph\'s Care Group
Tourette Syndrome Association
TOVA Company (The)
Tsehootsooi Medical Center
U.S. Department of State, Office of Medical Services
U.S. Department of Veterans Affairs
U.S. Department of Veterans Affairs
U.S. Psychiatric & Mental Health Congress
Universal Health Services, Inc.
University of Florida Health Department of Psychiatry
Uskudar University Npistanbul Neuropsychiatry Hospital
Valant Medical Solutions
Vanda Pharmaceuticals, Inc.
Vanderbilt Behavioral Health
VISTA Staffing Solutions, Inc.
Wolters Kluwer Health


text:
Decimal Degrees: Latitude: 34.8227965 Longitude: -111.7170985
Share your comments and photos of Lee Mountain, a Summit in Coconino County, AZ
(Optional) Upload a photo taken at this location:
Airport: Sedona Airport
Area: Devils Dining Room , Devils Kitchen , Grasshopper Point
Arroyo: Mortgage Draw
Bridge: Midgley Bridge
Cemetery: Sedona Memorial Park
Church: Chapel of the Holy Cross
Civil: City of Sedona
Flat: Grasshopper Flat , Little Park , Little Horse Park
Locale: Chavez Crossing Campground , Sedona Ranger Station , Grasshopper Point Campground , Schnebly Hill Vista
Park: Midgely Bridge Picnic Area
Populated Place: Sedona
Reserve: Munds Mountain Wilderness
Reservoir: Jacks Canyon Tank , Petes Water Haul , Corral Tank , Schnebly Tank , Committee Tank , Munds Tank , Steamboat Tank , Test Hole Tank
School: Sedona School
Spring: Lee Mountain Spring
Stream: Soldier Wash
Summit: Merry-Go-Round , Coffeepot Rock , Table Top Mountain , Munds Mountain , Bell Rock , Courthouse Butte , Cathedral Rock , Lee Mountain , Steamboat Rock
Trail: Casner Canyon Eleven Trail , Wilson Mountain Trail , Bridle Trail , Jack Canyon-Munds Mountain Fifty Five - Seventy Seven
Valley: Margs Draw , Bear Wallow Canyon , Damfino Canyon , Mormon Canyon , Wilson Canyon , Casner Canyon
49 Places found nearby
New! Tell others about this location or share a photo!
Time to build: 0.0470 Secs | Cached: 29-Mar-17 05:01 AM


text:
Spine and Back Health |
Moving My Leg Hurts My Back07/08/2009 |
I have back pain and my doctor gave me Norflex. When I lift my leg to straighten it I get an increase in pain in the milddle or the left side of my back between my shoulder blade and waist. I could see if it was the lower back because it is so close to my hip. Can you explain to me how moving my leg causes pain in the middle of my back?
Thank you for visiting NetWellness. On this site, NetWellness experts try to answer general questions about health. Only a health professional performing a thorough clinical exam is able to evaluate your symptoms. Best wishes.
NetWellness Staff NetWellness.org |


text: If I might be so presumptious as to illustrate what DWF is saying with an analogy that many here on teh StyleForvm will understand: It is like the difference between Americans and Canadians on one hand, and Europeans on the other. Americans and Canadians (and by "Canadian" I, of course, exclude French Canadians) tend to shower and bathe every day. This habit helps to remove microfine particles of ground rock, old coke bottles, etc. Europeans, in contrast, do not. They tend to rub lotion on their bodies and to douse themselves with cologne instead of bathing. This just moves the dirt around...including obsidian glass that settles on the body from the periodic eruptions of Vesuvius (a cone-shaped mountain near Naples.) I hope that was helpful. - B


text:
So at the risk of pissing off my wife, I blew off packing for a bit yesterday to answer the siren song of Craigslist. In addition to the rod and reel I posted earlier, I got a Tahoe clicker from the same guy for 5$. Then from another guy, I got a Hardy Marquis 8/9,an Orvis Clearwater that also drives on the wrong side of the road, and some odd clicky Daiwa thingy. It was a Gooooooood haul.
Yep. I was pretty stoked about so much gear for so cheap. As far as switching goes, trout fishing has always been my favorite.
Does the "odd clicky Diawa thingy" have a number on it? 700, 710 or 720. If so it is a well made Hardy clone. The best of the Hardy clones Heddon's, Berkley's, and Daiwa's are good reels at a much lower price than the equivalent Hardy's. TC
735, I think. It has 2 handles like a Centerpin reel. Makes a helluva racket when you pull line off of it. I think I'm going to fish it in the salt.
The fish may disagree with that, Ed. They seem to have their own schedule. If you are not there at lunch time, you don't get the takes. Or maybe it is just my deodorant or karma.


text:
The Himmatwala crew, it seems, is totally clueless about which films qualify to be remade and which ones deserve to be left alone
When Sridevi was asked whether she was happy with her old film Himmatwala being remade, the yesteryear diva simply said that it was no Mughal-e-Azam that it warranted a remake. Sure, it was a frivolous statement made by Sridevi, and understandably, the most upset with that remark was director Sajid Khan, who immediately began fuming at it.
Sajid minced no words in saying that Sridevi should to be glad that she got a chance to do a film like Himmatwala which made her a top star. "Sridevi became a star because of Himmatwala. I think Himmatwala is no less than Mughal-e-Azam for her," was his retort. A biting jibe for sure, but he also went on to add that Sridevi had all the right to air her views, and that would not change anything about his decision to remake the classic.
And now, to complicate things further, look what the film's lead star Ajay Devgn has said in a recent interview, "That is why we did Himmatwala because it was no Mughal-e-Azam. We would never try to attempt a Mughal-e-Azam, because we could never try to beat a Mughal-e-Azam. We can only do films which we have got the ingredients for and feel that we can better."
Now this is truly confusing. So while Sajid Khan feels Himmatwala is a Mughal-E-Azam for Sridevi, his lead hero says, it isn't one! Now before it gets murkier than it already is, can we please ask all the concerned parties to leave Mughal-e-Azam alone. It is a classic, and if someone feels they can remake it, then why not. Same for Himmatwala. If you can buy the rights, go ahead and make it. No point creating media frenzy and dragging poor K Asif's classic in the middle! And that goes for Sridevi too!


text: Star Wars characters holding bunnies. Human art was meant to culminate in this moment.Cyriaque Lamar10/02/12 4:15pmFiled to: Cheer UptweetFbMoviesStar Wars46EditPromoteShare to KinjaToggle Conversation toolsGo to permalink Bad news, artists. Humanity has fulfilled its aesthetic potential with this series of paintings by Kelly Kerrigan. Everybody out of the art pool and go home. C'mon, shoo. There are no more zeniths left to scale. I'm putting a lock on the art fence. Anyone who's stuck inside will be considered a trespasser and arrested by the art sheriff. [Via Boing Boing]Reply46 repliesLeave a reply


text:
#6281 closed enhancement (worksforme)
Slots for animations
Reported by: | AzaToth | Owned by: | |
Priority: | low | Milestone: | 1.6 |
Component: | effects | Version: | 1.4.2 |
Keywords: | Cc: | ||
Blocked by: | Blocking: |
This patch adds slots to the fx mechanism and results in that all animations in a given slot will use the same time quanta.
Attachments (3)
Change History (14)
Changed 7 years ago by AzaToth
comment:1 Changed 7 years ago by AzaToth
A more detailed reason for this:
When multiple animations are meant to be executed in "parallel", currently they will be asynchronous and thus experience an delayed animation for later elements. To overcome this issue, we add an slot mechanism which specifies that we can use one single slot for a bunch of animations, and they all will use the same start time and current time.
comment:2 Changed 7 years ago by AzaToth
Here is a visual test; the "normal" is what current behavior is, and slotted is when the effect uses the same slot:
Changed 7 years ago by AzaToth
updated patch to remove the requirement to call reset on chained animations
comment:3 Changed 7 years ago by AzaToth
See http://js.azatoth.net/test/slotted2.html for example using second patch.
comment:5 Changed 6 years ago by snover
- Priority set to low
- Status changed from new to open
comment:7 Changed 6 years ago by dmethvin
#7490 is a duplicate of this ticket.
comment:8 Changed 6 years ago by grevian+jquery@…
Would it be possible to have a callback added for when all elements in a particular slot have finished execution? Also I find the terminology of "slot" to be a little odd, wouldn't "set" or "group", possibly prefixed like "fxgroup" or "AnimationSet" be more appropriate?
comment:9 Changed 6 years ago by gnarf
Another approach to synchronizing animations - http://bugs.jquery.com/ticket/7917 - I opened it having not found this ticket while searching.
comment:10 Changed 6 years ago by AzaToth
Added pull request at https://github.com/jquery/jquery/pull/271
comment:11 Changed 6 years ago by john
- Milestone set to 1.6
- Resolution set to worksforme
- Status changed from open to closed
This was fixed with the resolution of #7917.


text:
Business Plus Baby
Growing a business around a young family
Handmade Horizons
Popular Posts and Resources
Tutorial: How to start your own online store
Come say 'hi' over at the Business Plus Baby Facebook page.
Looking for a web host? I use and recommend Clook.
Can you claim childcare costs as a business expense?
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.


text:
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
© Strand et al.; licensee BioMed Central Ltd. 2013
Received: 21 December 2012
Accepted: 7 May 2013
Published: 10 May 2013
Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production.
Apremilast's effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, controlled trial (NCT00773734).
In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received placebo or apremilast (10, 20, or 30 mg BID). PROs included Dermatology Life Quality Index (DLQI), pruritus visual analog scale (VAS), and Short-Form Health Survey (SF-36) to assess health-related quality of life (HRQOL). Changes from baseline and patients reporting improvements ≥minimum clinically important differences (MCID) were analyzed. Correlations between changes across various PRO instruments were explored.
Baseline DLQI (>10 points) and SF-36 MCS and domain scores indicated impairments in HRQOL. At 16 weeks, greater improvements from baseline in DLQI scores were reported with apremilast 20 (−5.9) and 30 mg BID (−4.4) compared with placebo (1.9; P≤0.005 for both), and a greater proportion of patients reported improvements ≥MCID (20 mg BID, 49.4%, 30 mg BID, 44.3%) versus placebo (25.0%; P<0.04). Greater improvements from baseline in pruritus VAS scores were reported with apremilast 20 (−35.5%) and 30 mg BID (−43.7%) versus placebo (−6.1%; P≤0.005). Significant and clinically meaningful improvements in SF-36 mental component summary scores (P≤0.008) and Bodily Pain, Mental Health, and Role-Emotional domains were reported with all apremilast doses (P<0.05), and Social Functioning with 20 and 30 mg BID (P<0.05) and Physical Functioning with 20 mg BID (P<0.03). Correlations between SF-36 scores and DLQI were moderate (r>0.30 and ≤0.60) and low between SF-36 and pruritus VAS (r≤0.30), indicating they measure different aspects of the disease.
Apremilast treatment resulted in improved HRQOL, including DLQI and pruritus VAS over 16 weeks of treatment, in patients with moderate to severe psoriasis.
Apremilast Dermatology Life Quality Index Phosphodiesterase 4 Psoriasis Quality of life SF-36Background
Psoriasis is a chronic inflammatory disease that affects approximately 1% to 3% of the worldwide population [1, 2]. Individuals with psoriasis report impaired health-related quality of life (HRQOL), ranging from physical discomfort and limitations in activities of daily living to psychosocial problems and emotional distress [3–7]. Furthermore, the severity of psoriasis symptoms, and pruritus in particular, has been linked to the degree of HRQOL impairment [3, 4].
Many therapies for psoriasis treatment improve HRQOL [8–10]. Despite this, each therapy's benefit can be compromised by poor tolerability, adverse events, and route of administration (particularly injection/infusion reactions) [11, 12]. These limitations underscore the persistent unmet need for additional treatment options for psoriasis [13]. As new therapies become available for managing psoriasis, it is important to evaluate their impact on patient-reported HRQOL.
Research over the past decade in inflammatory diseases such as psoriasis has focused upon modulation of cyclic adenosine monophosphate (cAMP), a naturally occurring intracellular secondary messenger that maintains immune homeostasis by modulating production of pro-inflammatory and anti-inflammatory cytokines [14, 15]. Phosphodiesterase 4 (PDE4) is a cAMP-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP, which in turn down-regulates the inflammatory response [16–19]. Apremilast (CC-10004; Celgene Corporation, Summit, NJ, USA) is a small molecule that specifically inhibits PDE4, thereby elevating intracellular cAMP levels. Elevated intracellular cAMP reduces pro-inflammatory mediators, such as tumor necrosis factor-α, interleukin-23, and interferon-γ, and increases production of anti-inflammatory mediators, such as interleukin-10 [18]. Clinical studies have demonstrated the efficacy and tolerability of apremilast in moderate to severe psoriasis and psoriatic arthritis (PsA) [20–22].
In this phase IIb, multicenter, randomized, controlled trial (RCT), orally administered apremilast (10 mg BID, 20 mg BID, or 30 mg BID) resulted in dose-dependent efficacy for the treatment of moderate to severe plaque psoriasis [20]. A significantly greater proportion of patients receiving apremilast 20 mg (28.7%) and 30 mg BID (40.9%) achieved ≥75% mean reductions from baseline in Psoriasis Area and Severity Index (PASI-75) scores compared with placebo (P<0.001) after 16 weeks of treatment [20]. Reductions in baseline PASI scores were evident by week 2, with a separation across doses observed by weeks 2 to 4; improvements were maintained over 24 weeks' treatment. Significant improvements in pruritus visual analog scale (VAS), static Physician's Global Assessment, and body surface area (BSA) scores were also reported. It is hypothesized that clinical improvements would be accompanied by improvements in patient-assessed HRQOL. This report summarizes the impact of apremilast on patient-reported outcomes (PROs) over the initial 16-week placebo-controlled treatment phase of this trial.
Materials and methods
Study design
This phase IIb RCT was conducted at 35 sites in the United States and Canada between September 2008 and November 2009. Methods, including enrollment, study design, and procedures, have been previously published [20]. Briefly, men and women ≥18 years of age with stable, chronic, moderate to severe plaque psoriasis (PASI ≥12 and BSA ≥10% for ≥6 months) who were candidates for phototherapy or systemic therapy were enrolled and randomized 1:1:1:1 to receive apremilast 10, 20, or 30 mg BID or placebo for 16 weeks. At week 16, placebo patients were re-randomized 1:1 to apremilast 20 or 30 mg BID until week 24 in blinded fashion; all other patients continued their assigned dose of apremilast. Throughout the trial, concomitant phototherapy and use of systemic and biologic agents were prohibited. Use of topical agents was also prohibited, with the exception of Eucerin® cream for body lesions; low-potency corticosteroids for facial, axillary, and groin psoriasis lesions; and coal tar shampoo or salicylic acid preparations for scalp lesions. All patients provided written informed consent before study-related procedures were done, and the protocol and consent were approved by institutional review boards or ethics committees at all investigational sites.
PRO assessments
Instrument | Description | Scale | MCID |
Pruritus VAS | ● Pruritus visual analog scale | 0–100 mm, including "anchors" | 10.0 points |
(best to worst) | |||
DLQI | ● Dermatology Life Quality Index | 0–30 points | 5.0 points |
● Subject report, 10 questions addressing: | (best to worst) | ||
– Symptoms | |||
– Feelings | |||
– Daily activities | |||
– Leisure | |||
– Work | |||
– Personal relationships | |||
SF-36 domains* | ● Patient report, 36 items | 0–100 mm | 5.0 points |
– Physical Functioning | (worst to best) | ||
– Role-Physical | |||
– Bodily Pain | |||
– General Health | |||
– Vitality | |||
– Role-Emotional | |||
– Social Functioning | |||
– Mental Health | |||
SF-36 PCS and MCS scores | ● Calculated based upon domain scores | Normative value: mean=50, SD=10 | 2.5 points |
End points and statistical analysis
PROs were evaluated based on the intent-to-treat population using last-observation-carried-forward (LOCF) to account for missing values. Week 16 changes from baseline in DLQI and SF-36 scores were examined using ANCOVA, with treatment as a factor and baseline as a covariate. Week 16 percent change from baseline in mean pruritus VAS scores was compared using the Wilcoxon test for each apremilast group versus placebo. If either PCS and/or MCS scores of SF-36 were statistically significant, significance was tested for the individual domain scores, without P value corrections for multiplicity. Mean changes from baseline in domain scores are displayed using spydergrams [29], with quantification of improvements using the health utility SF-6D measure, after the method of Ara and Brazier [30, 31]. As a benchmark comparison, US normative data were calculated based on age and gender distribution of the protocol population [32]. Pearson correlations (r) were determined for mean changes from baseline between the generic SF-36 Bodily Pain (BP) and Vitality (VT) domains and MCS scores at week 16 with disease-specific DLQI and pruritus VAS scores. Correlations >0.30 to ≤0.60 were considered moderate and >0.60 high [33]. These were unplanned, post hoc analyses based on results from secondary analysis of PROs, with the P values presented for inferential use.
Baseline demographic and clinical characteristics of the enrolled population
Characteristic | Placebo (n=88) | Apremilast BID | Total (N=352) | ||
10 mg (n=89) | 20 mg (n=87) | 30 mg (n=88) | |||
Age (years) | 44.1 ± 13.7 | 44.4 ± 14.0 | 44.6 ± 12.6 | 44.1 ± 14.7 | 44.3 ± 13.7 |
Male | 53 (60.2) | 63 (70.8) | 55 (63.2) | 50 (56.8) | 221 (62.8) |
Race | |||||
White | 83 (94.3) | 82 (92.1) | 82 (94.3) | 80 (90.9) | 327 (92.9) |
Black | 1 (1.1) | 2 (2.2) | 1 (1.1) | 2 (2.3) | 6 (1.7) |
Asian | 4 (4.5) | 3 (3.4) | 2 (2.3) | 4 (4.5) | 13 (3.7) |
Other | 0 (0.0) | 2 (2.2) | 2 (2.3) | 2 (2.3) | 6 (1.7) |
Height (cm) | 171.2 ± 8.6 | 171.5 ± 10.2 | 171.7 ± 9.6 | 171.2 ± 10.7 | 171.5 ± 9.6 |
Weight (kg) | 90.3 ± 21.4 | 95.7 ± 23.2 | 89.9 ± 20.2 | 91.2 ± 23.1 | 91.8 ± 22.0 |
BMI (kg/m2) | 30.8 ± 6.7 | 32.5 ± 7.4 | 30.4 ± 6.2 | 31.1 ± 7.8 | 31.2 ± 7.1 |
Total PASI score | 18.1 ± 5.7 | 18.1 ± 6.3 | 18.5 ± 7.3 | 19.1 ± 7.1 | 18.5 ± 6.6 |
+ History PsA | 17 (19.3) | 20 (22.5) | 16 (18.4) | 21 (23.9) | 74 (21.0) |
Plaque psoriasis history (years) | 19.6 ± 11.6 | 18.0 ± 12.4 | 19.2 ± 12.2 | 19.2 ± 12.0 | 19.0 ± 12.0 |
Previous systemic therapy for psoriasis | 39 (44.3) | 47 (52.8) | 43 (49.4) | 47 (53.4) | 176 (50.0) |
PRO assessments
Summary DLQI and pruritus VAS scores at week 16
Patient-reported outcome | Placebo (n=88) | Apremilast BID | ||
10 mg (n=89) | 20 mg (n=86) | 30 mg (n=88) | ||
Baseline | 10.7 ± 6.7 | 10.8 ± 6.3 | 11.6 ± 7.0 | 10.6 ± 6.2 |
Week 16 | 8.6 ± 7.6 | 7.6 ± 6.3 | 5.8 ± 6.0 | 6.0 ± 6.2 |
Change from baseline | −1.9 ± 5.2 | −3.2 ± 6.0 | −5.9 ± 6.7* | −4.4 ± 5.1* |
Pruritus VAS | ||||
Baseline | 55.5 ± 25.5 | 54.1 ± 23.5 | 58.3 ± 26.7 | 55.3 ± 25.5 |
Week 16 | 45.6 ± 30.2 | 39.0 ± 27.8 | 35.2 ± 29.2 | 31.6 ± 30.0 |
Percent change from baseline | −6.1 ± 76.4 | −10.2 ± 100.8 | −35.5 ± 66.0* | −43.7 ± 46.8* |
Pruritus VAS
Baseline pruritus VAS scores were well matched across treatment groups (Table 3). Significantly greater reductions from baseline in mean pruritus scores at week 16 were reported with apremilast 20 mg BID (P=0.005) and 30 mg BID (P<0.001), but not with 10 mg BID (P=0.366) versus placebo. Thirty-nine (44.3%) placebo, 47 (52.8%) apremilast 10 mg BID (P=0.294), 53 (60.9%) 20 mg BID (P=0.034 vs. placebo), and 56 (63.6%) 30 mg BID patients (P=0.015) reported improvements ≥MCID.
SF-36 MCS and PCS scores
SF-36 domain scores
At baseline, SF-36 domain scores were generally well matched between study groups and equaled or were within 10 points of age- and gender-matched normative scores. At week 16, no significant changes from baseline in any domain were evident in the placebo group.
Correlations among DLQI, pruritus VAS, and SF-36 scores
Correlations of changes in SF-36 BP, VT, and MCS scores with changes in DLQI and pruritus VAS scores at week 16
Placebo | Apremilast BID | |||
10 mg | 20 mg | 30 mg | ||
SF-36 BP with DLQI | −0.45* | −0.32* | −0.52* | −0.35* |
SF-36 VT with DLQI | 0.38* | −0.18 | −0.33* | −0.23 |
SF-36 MCS with DLQI | −0.57* | −0.41* | −0.42* | −0.31* |
SF-36 BP with pruritus VAS | −0.39* | −0.27 | −0.43* | −0.30 |
SF-36 VT with pruritus VAS | −0.36* | 0.01 | −0.11 | −0.23 |
SF-36 MCS with pruritus VAS | −0.35* | −0.21 | −0.12 | −0.35* |
In this RCT, patients with moderate to severe plaque psoriasis reported impairments in disease-specific and generic measures of HRQOL at baseline, evidenced by mean DLQI scores >10 and SF-36 MCS scores 0.5 SDs below US age-/gender-matched norms. Statistically significant and clinically meaningful improvements in SF-36 MCS and domain scores were reported by patients treated with apremilast, most evident in the 20- and 30-mg BID dose groups, mirrored by decreases in disease-specific DLQI and pruritus VAS scores. In contrast, patients receiving placebo reported little change or deterioration from baseline in HRQOL. Correlations between SF-36 MCS, BP, and VT scores and DLQI were moderate and, in general, statistically significant. Correlations between SF-36 scores and pruritus VAS were moderate to low, indicating that they measure different impacts of the disease and highlighting the value in assessing efficacy using multiple instruments.
Interpretation and implications
Growing evidence clearly shows that impairments in HRQOL are a large component of the disease burden imposed by psoriasis. These results are in line with national survey findings that show the majority of individuals with psoriasis experience emotional as well as physical disease-related problems [34]. In that survey, 63% of respondents reported that psoriasis impacts their emotional well-being, marked by feelings of helplessness, anger, embarrassment, and frustration. Given the generally high level of emotional distress patients report regarding psoriasis symptoms, it is important to describe the potential impact of treatment on emotional functioning. Emotional distress has been linked to onset of psoriasis flares, more severe symptoms, and presence of lesions in visible locations [3, 35] and may contribute to heightened risk of major depressive disorder, often seen in this patient population [5, 6, 36]. This trial contributes to other RCT data demonstrating that efficacious treatment of moderate to severe psoriasis results in improvements in HRQOL [7–9, 37, 38]. Consistent with findings from other studies [7], psoriasis appears to have relatively greater impact on mental health rather than physical domains, as patients report larger decrements in RE and SF and to a lesser degree BP domains. This suggests that the impact of physical well-being on mental health might well depend on the nature of the physical impairment, as skin disease may have a disproportionately large effect on mental functioning and ensuing HRQOL whereas joint disease in PsA has more impact on PF, BP, and VT domains. These data demonstrate moderate correlations between improvements in disease-specific functioning, based on DLQI, and broader improvements in SF-36 MCS scores and BP, SF, and RE domains. This likely reflects improvements in painful psoriatic plaques and/or joint pain associated with comorbid PsA, although only a minority of patients reported the presence of arthritis. The ability to measure treatment efficacy based on broader generic instruments has implications when considering comparisons with normative populations as well as across disease states. Disease-associated decrements in HRQOL reported by patients with psoriasis indicate that a multipronged approach could enhance assessment of treatment effectiveness. This approach should encompass clinical signs and symptoms, as well as patient-reported HRQOL, using both disease-specific and generic instruments.
Apremilast clinical data
As described in a separate report [20], the primary results of this study demonstrate the efficacy and tolerability of apremilast 20 and 30 mg BID over 24 weeks in patients with moderate to severe plaque psoriasis, including significant improvements in PASI, pruritus, static Physician's Global Assessment, and BSA scores. The most frequently reported adverse events were headache, nausea, vomiting, nasopharyngitis, and upper respiratory tract infection. The majority of adverse events (>96%) were mild or moderate in severity, and rates of discontinuations due to adverse events were generally low (≈10%). Gastrointestinal events were generally transient. Importantly, no opportunistic infections were reported, and no serious infections were considered related to apremilast [20].
The tolerability findings are important in their relationship to the improved HRQOL seen in this study. While improvement in the severity of disease can be expected in most cases to improve HRQOL, there are some instances in which tolerability and safety issues may abrogate this benefit. The results of the current analysis indicate that this was not the case with apremilast. While the most commonly reported adverse events were related to gastrointestinal complaints and headache, this did not appear to outweigh the benefit of therapy, and resulted in an overall improvement in HRQOL.
On the basis of phase II findings, further examination of the efficacy and safety of apremilast for the treatment of psoriasis is underway in phase III studies. The ESTEEM (E fficacy and S afety T rial E valuating the E ffects of apreM ilast in psoriasis) clinical trial program includes two 52-week RCTs, each with a 16-week placebo-controlled phase, randomized withdrawal phase for PASI responders, and long-term, open-label extension to assess the efficacy, tolerability, and effects of apremilast on HRQOL in patients with moderate to severe plaque psoriasis. Recently, topline results from the ESTEEM 1 trial were presented [39]. At week 16, a significantly greater proportion of patients receiving apremilast 30 mg BID achieved PASI-75 (33.1%) and PASI-50 (58.7%) compared with placebo (5.3% and 17.0%; P<0.0001 for both). Apremilast was also associated with significant improvements in static Physician's Global Assessment, pruritus VAS, and DLQI as well as difficult-to-treat nail and scalp psoriasis. Apremilast was well-tolerated and no new safety or laboratory signals were detected. Additional results are anticipated. In addition, apremilast is currently being investigated in phase III clinical trials for the treatment of PsA and ankylosing spondylitis.
The study enrolled patients with moderate to severe plaque psoriasis and results may not be applicable to patients with other forms of psoriasis. This report is based on PROs after 16 weeks of treatment, although a separate publication indicates that improvements with active therapy are generally maintained over 24 weeks of treatment [20]. Ongoing phase III studies are expected to yield valuable information.
Moderate to severe plaque psoriasis is associated with a negative impact on HRQOL, including pain and social and emotional functioning. Assessment of clinical signs and symptoms, as well as PROs, is useful in determining the impact of psoriasis and the clinical efficacy of treatment. In this study, apremilast 20 mg and 30 mg BID consistently resulted in statistically significant and clinically meaningful improvements in disease-specific and generic measures of HRQOL in patients with long-standing, moderate to severe plaque psoriasis. Findings indicate that the benefit:risk profile of apremilast results in a net improvement in HRQOL for the patient.
Bodily Pain [cap p]
Body surface area
- cAMP:
Cyclic adenosine monophosphate
Dermatology Life Quality Index
Health-related quality of life
Last observation carried forward
Minimum clinically important differences
Mental component summary
≥75% mean reductions from baseline in Psoriasis Area and Severity Index
Phosphodiesterase 4
Physical component summary
Physical Functioning
- PROs:
Patient-reported outcomes
- PsA:
Psoriatic arthritis
Randomized, controlled trial
- SDs:
Standard deviations
Social Functioning
36-item Short-Form Health Survey
Visual analog scale
This study was sponsored by Celgene Corporation. The authors received editorial support in the preparation of this manuscript from Peloton Advantage, LLC, and Jennifer Schwinn, RPh, funded by Celgene Corporation. The authors, however, directed and are fully responsible for all content and editorial decisions for this manuscript.
Authors' Affiliations
- Kurd SK, Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009, 60: 218–224. 10.1016/j.jaad.2008.09.022PubMedView ArticleGoogle Scholar
- Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010, 90: 147–151. 10.2340/00015555-0770PubMedView ArticleGoogle Scholar
- Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y: The psychosocial burden of psoriasis. Am J Clin Dermatol 2005, 6: 383–392. 10.2165/00128071-200506060-00005PubMedView ArticleGoogle Scholar
- Reich A, Hrehorow E, Szepietowski JC: Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010, 90: 257–263.PubMedView ArticleGoogle Scholar
- Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, Sid-Mohand D, Le Pen C, Ortonne JP: Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010, 24: 1075–1082.PubMedGoogle Scholar
- Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM: The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010, 146: 891–895. 10.1001/archdermatol.2010.186PubMed CentralPubMedGoogle Scholar
- Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D: Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012, 17: 1143–1150.View ArticleGoogle Scholar
- Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A: Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005, 153: 1192–1199. 10.1111/j.1365-2133.2005.06948.xPubMedView ArticleGoogle Scholar
- Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG: Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010, 162: 137–146. 10.1111/j.1365-2133.2009.09491.xPubMedView ArticleGoogle Scholar
- Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366: 1367–1374. 10.1016/S0140-6736(05)67566-6PubMedView ArticleGoogle Scholar
- Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM: High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010, 220: 128–137. 10.1159/000275198PubMedView ArticleGoogle Scholar
- Ravindran V, Scott DL, Choy EH: A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008, 67: 855–859. 10.1136/ard.2007.072652PubMedView ArticleGoogle Scholar
- Richards HL, Fortune DG, Griffiths CE: Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006, 20: 370–379. 10.1111/j.1468-3083.2006.01565.xPubMedView ArticleGoogle Scholar
- Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M: Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 2008, 39: 127–132. 10.1165/rcmb.2008-0091TRPubMed CentralPubMedView ArticleGoogle Scholar
- Tasken K, Aandahl EM: Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004, 84: 137–167. 10.1152/physrev.00021.2003PubMedView ArticleGoogle Scholar
- Houslay MD, Schafer P, Zhang KY: Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005, 10: 1503–1519. 10.1016/S1359-6446(05)03622-6PubMedView ArticleGoogle Scholar
- Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M: Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007, 6: 17–26. 10.2174/187152807780077318PubMedView ArticleGoogle Scholar
- Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung Y-F, Baillie GS, Houslay MD, Man H-W, Muller GW, Stirling DI: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010, 159: 842–855. 10.1111/j.1476-5381.2009.00559.xPubMed CentralPubMedView ArticleGoogle Scholar
- Salari P, Abdollahi M: Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012, 21: 261–264. 10.1517/13543784.2012.658915PubMedView ArticleGoogle Scholar
- Papp K, Cather J, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu A, Day RM: The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: results of a phase 2 randomised study. Lancet 2012, 380: 738–746. 10.1016/S0140-6736(12)60642-4PubMedView ArticleGoogle Scholar
- Schett G, Wollenhaupt J, Papp K, Joos R, DeVlam KL, Rodrigues JF, Vessey A, Hu CC, Stevens R: Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64: 3156–3167. 10.1002/art.34627PubMedView ArticleGoogle Scholar
- Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C: An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008, 24: 1529–1538. 10.1185/030079908X301866PubMedView ArticleGoogle Scholar
- Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY: The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008, 159: 997–1035.PubMedGoogle Scholar
- Strand V, Bombardier C, Maetzel A, Scott D, Crawford B: Use of minimum clinically important differences (MCID) in evaluating patient responses to treatment of rheumatoid arthtitis (RA) [abstract 810]. Arthritis Rheum 2001,44(suppl 9):S187.Google Scholar
- Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B: Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005, 32: 590–601.PubMedGoogle Scholar
- Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P: Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010, 49: 1900–1910. 10.1093/rheumatology/keq109View ArticleGoogle Scholar
- Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A: Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000, 43: 506–514. 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-UPubMedView ArticleGoogle Scholar
- Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005, 125: 659–664. 10.1111/j.0022-202X.2005.23621.xPubMedView ArticleGoogle Scholar
- Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D: Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009, 68: 1800–1804. 10.1136/ard.2009.115550PubMed CentralPubMedView ArticleGoogle Scholar
- Ara R, Brazier J: Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008, 11: 1131–1143. 10.1111/j.1524-4733.2008.00352.xPubMedView ArticleGoogle Scholar
- Ara R, Brazier J: Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health 2009, 12: 346–353. 10.1111/j.1524-4733.2008.00428.xPubMedView ArticleGoogle Scholar
- Ware J, Kosinski M, Dewey JE: How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI: QualityMetric Inc.; 2000.Google Scholar
- Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.; 1988.Google Scholar
- National Psoriasis Foundation: Report on the Psycho-Social Impacts of Psoriasis. [http://www.psoriasis.org/Document.DOC?id=619]
- Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A: The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000, 14: 267–271. 10.1046/j.1468-3083.2000.00085.xPubMedView ArticleGoogle Scholar
- Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008, 58: 1031–1042. 10.1016/j.jaad.2008.01.006PubMed CentralPubMedView ArticleGoogle Scholar
- Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM: Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011, 12: 51–62. 10.2165/11530640-000000000-00000PubMedView ArticleGoogle Scholar
- Flytstrom I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008, 158: 116–121.PubMedGoogle Scholar
- Reich K: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1) [oral presentation]. Miami, FL: Presented at: the 71st Annual Meeting of the American Academy of Dermatology; 2013.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


text:
Attention All WebMD Community Members:
These message boards are closed to posting. Please head on over to our new WebMD Message Boards to check out and participate in the great conversations taking place: https://messageboards.webmd.com/
Your new WebMD Message Boards are now open!
Making the move
is as easy as 1-2-3.
1. Head over to this page: https://messageboards.webmd.com/living-healthy/f/mens-health/
2. Choose the tag from the drop-down menu that
clicks most with you (and add it to any posts you create so others can easily
find and sort through posts)
3. Start posting
Have questions? Email us anytime at firstname.lastname@example.com
Helpful Tips
Discharge from Penis(Penile Discharge)
Penile discharge is the abnormal loss of fluid that is not urine or semen from the urethra (urine tube) at the tip of the penis. It is ... More
2 found this helpful
Related News
Report Problems With Your Medications to the FDA
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


text:
Abt Card
Product Questions - Ask
Average Customer Reviews
In a Class of Its Own. Loaded with first-of-its-kind features and high-end capabilities, the Canon PowerShot SD4000 IS Digital ELPH gives ELPH lovers all new reasons to step up. Never before has Canon equipped an ELPH with a back-illuminated CMOS sensor-driven HS SYSTEM or an f/2.0 lens - both of which deliver incredible images in low light. And shooting action or sporting events has never been so fun, with High-Speed Burst mode and the Super Slow Motion Movie function to mix things up. You'll control shots like a pro with Aperture- and Shutter-priority modes, and play your 720p HD movies effortlessly on your HDTV. All this from a super-slim style icon - what more could you ask?
Package Content:
Type of Camera
Image Capture Device
Viewfinder & Monitor
Aperture and Shutter
Exposure Control
White Balance
Shooting Specifications
Image Storage
Playback Specifications
Erasing Specifications
Power Supply
Physical Specifications
Approximate Dimensions:
Approximate Weight:
Warranty Information:
(based on 2 reviews)
Ratings Distribution
5 Stars
4 Stars
3 Stars
2 Stars
1 Stars
Reviewed by 2 customers
Displaying reviews 1-2
Back to top
(3 of 3 customers found this review helpful)
The best digital camera we ever owned. very happy
By ally oop
from Indiana
Best Uses
Comments about Canon PowerShot SD4000 IS Silver 10 Megapixel Digital Camera:
We could reecommend this camera to anyone. wE are very happy with ours. We get good quality photos with ours. It is small enough to carry, but does the job of a much bigger camera.
(2 of 2 customers found this review helpful)
I LOVE this camera!
By RF
from Chicago, Illinois
About Me Casual Photographer
I ordered this camera just before our vacation [...] It was fun and pretty easy to use. Took some time to be able to use special features and am still learning. I have owned a few Canon cameras and this is by far my favorite. Best pictures and most features. Takes very good pictures in low light.
Fill out the form below to request Better Price for this product.


text:
via 500px http://ift.tt/1KUeDdU
via 500px http://ift.tt/1KUeDdU
hiking, healthy eating, minimalism
Fun, delicious recipes the whole family will enjoy!
Homemade cooking with healthy seasonal ingredients
20 something year old bun, bakes, studies, eats
A Registered Dietitian helping individuals learn how to fuel their bodies with whole, nutrient rich foods
Looking forward to the future while being grateful for the past
if you are depressed or in trouble, read my posts
Making the world a richer place, one story at a time
Nurses are Angels in Scrubs
Let The Words Get Freedom & Thoughts A Stage
a 100-word story every day
Focus Hocus Pocus
A ripple of love, light, peace and hope
Shimmering thoughts on life's journey
... INNA HUDALLAHI HUWAL HUDA (Katotohanan, ang gabay ni Allah ang tunay na gabay)...." [Al-Baqarah 2:120]
Welcome to our site. We hope you'll enjoy our pictures, photos and poetry and find inspiration from our ramblings.
Bringing the world to you!
A Place of Inspiration, Empowerment, and Love
Just trying to help out.
A little lifestyle blog.
Making the most of your mid life crisis
Cleveland's Classic Rock
Here goes nothing...
Live The Laptop Life Style
Live A Curious Life
A Monthly Ezine created by Sharmishtha Basu- some fiery and some sweet words.
A Food and Exercise Diary
a hungry girl navigating the chicago food scene
making room at the table for other people. and their stuff.
Living Vegan In Charlotte, NC - Easy Vegan Recipes - Vegan Restaurant, Product, and Cookbook Reviews
Faith, Family, Friends, & Food
Chronicles from the Mama Duck - Raising teenagers...family...faith...
Living Free with disAbilities
"And that is how change happens. One gesture. One person. One moment at a time."
A medical student's prescription for creativity measured by life's dosage
Life Matters | Fitness/Zumba | Losing Weight | Real Estate
Faith, Family and Everyday Life.
News, Weather, Traffic and Sports for Grand Rapids and West Michigan.
Motivation and life......lived and loved one day at a time.
My journey to living a full and healthy life while inspiring others every step of the way.
W.O.W Mckendree University
Encouragement & Insight into Jesus, Business, and Life in Christ.


text:
Take a tour
Success Stories
invite your friends
success stories
- Select Menu -
Invite your friends
Success Stories
Mon. Jan 1, 12:00am
It sounds like premature ejaculation, which is common. You should read up on it and maybe gently see if you can prolong things or add some variety to the length of time before he ejaculates.
Be gentle, we all have delicate egos about sex! :)
Wednesday, February 13, 2008, 12:04 AM
If he's under 25, it's not that unusual.
Wednesday, February 13, 2008, 12:37 AM
Not uncommon at all.
Wednesday, February 13, 2008, 8:42 AM
tell him to wear two condoms--less sensitive for him and he will last longer.
also, don't be consistent with the rythm. mix it up, that helps quite a bit.
Wednesday, February 13, 2008, 10:27 AM
how about a condom with a a numbing cream on the inside so it affects him and not you. i've heard those work really well.
this reminds me of a really funny curb your enthusiasm episode... larry david wore it inside out and made cheryl's vagina numb for days. funny stuff.
Wednesday, February 13, 2008, 11:04 AM
I had a boyfriend like this for awhile, though it was more like 30 seconds than 5 minutes...
It takes work, no doubt, but you've got time. Encourage him to slow down or stop when he is getting too close, and even pull out and take a break. Doing this over and over will eventually teach him how to control himself better, and make him able to last longer. It wil be frusterating during the process though!
When he takes breaks, he can still do things for you - touching, licking, etc. - so that it is less frusterating.
Good luck!
Wednesday, February 13, 2008, 2:42 PM
Related Content:
How To Lose Weight- The Basics
Weight Watchers Points System
The Fat Smash Diet
The Eat To Live Diet
The Beck Diet Solution
How To Get The Motivation To Lose Weight
How To Be Successful Using PEERtrainer
How To Burn Fat
Online Weight Loss Support- How It Works
Does Green Tea Help You Lose Weight?
Tips On Using PEERtrainer
Visit The PEERtrainer Community
Diet and Fitness Resources
Weight Watchers Meetings
Learning To Inspire Others: You Already Are
Writing Down Your Daily Workouts
Spending Money On A Personal Trainer?
How I Became A Marathon Runner
Preventive Health
How To Prevent Injuries During Your Workout
Flu Season: Should You Take The Flu Shot?
Are You Really Ready To Start PEERtrainer?
Super Foods That Can Boost Your Energy
Reversing Disease Through Nutrition
New Diet and Fitness Articles:
Weight Watchers Points Plus
How To Adjust Your Body To Exercise
New: Weight Watchers Momentum Program
New: PEERtrainer Blog Archive
Review Of The New Weight Watchers Momentum Program
Weight Loss Motivation by Joshua Wayne:
Why Simple Goal Setting Is Not Enough
How To Delay Short Term Gratification
How To Stay Motivated
How To Exercise With A Busy Schedule
Real World Nutrition and Fitness Questions
Can Weight Lifting Help You Lose Weight?
Are Protein Drinks Safe?
Nutrition As Medicine?
Everyday Weight Loss Tips
How To Eat Healthy At A Party
How To Eat Out And Still Lose Weight
The Three Bite Rule
Tips On How To Stop A Binge
Introducing The PEERtrainer Cheat System
How To Speed Up Weight Loss
How To Get Motivation To Lose Weight
Weight Watchers: The New Science!
3 Myths About Weight Loss With JJ Virgin
Related Article :
New PEERtrainer Articles :
Why Green Tea Helps You Lose Weight
How To Lose A Lot Of Weight, Fast
5 Things You Must Know Before Doing A Cleanse
New: How To Build Muscle
What Is The Best Kind Of Protein Powder?
The Master Cleanse
Will Removing Gluten From Your Diet Help You Lose Weight?
How To Obliterate Your Limitations
How To Get The Motivation To Exercise
How To Stop Feeling Tired
Dr. Joel Fuhrman's Super Immunity Diet
The PEERtrainer Diet
Is Portion Control Keeping You Fat?
The Ultimate Guide To Dietary Fiber
P90X? Do Burst Training Instead
Weight Watchers Points Changes For 2012
Can Diet Soda Cause You To GAIN Weight?


text:
Home | About WTO | News & events | Trade topics | WTO membership | Documents & resources | External relations
Contact us | Site map | A-Z | Search
español français
home > trade topics > dispute settlement > the disputes >
United States — Standards for Reformulated and Conventional Gasoline
This summary has been prepared by the Secretariat under its own responsibility. The summary is for general information only and is not intended to affect the rights and obligations of Members.
See also: > One-page summary of key findings of this dispute > The basics: how disputes are settled in WTO > Computer based training on dispute settlement > Text of the Dispute Settlement Understanding
Current status back to top
Key facts back to top
Summary of the dispute to date back to top
The summary below was up-to-date at See also: One-page summary of key findings of this dispute
Complaints by Venezuela and Brazil.
Venezuela requested consultations on 24 January 1995 and Brazil on 10 April 1995. Complainants alleged that a US gasoline regulation discriminated against complainants gasoline in violation of GATT Articles I and III and Article 2 of the Agreement on Technical Barriers to Trade (TBT).
Panel and Appellate Body proceedings
Further to Venezuelas request, the DSB established a Panel at its meeting on 10 April 1995. On 26 April 1995 the Panel was composed. Further to Brazils request, the DSB established a Panel at its meeting on 19 June 1995. On 31 May 1995, in accordance with Article 9 of the DSU, it was agreed that a single panel would consider the complaints of Venezuela and Brazil. The report of the panel was circulated to Members on 29 January 1996. The report of the panel found the regulation to be inconsistent with GATT Article III:4 and not to benefit from an Article XX exception.
The US appealed on 21 February 1996. On 22 April, the Appellate Body issued its report, modifying the panel report on the interpretation of GATT Article XX(g), but concluding that Article XX(g) was not applicable in this case. The Appellate Report, together with the panel report as modified by the Appellate Report, was adopted by the DSB on 20 May 1996.
Implementation of adopted reports
The US announced implementation of the recommendations of the DSB as of 19 August 1997, at the end of the 15 month reasonable period of time.
Find all documents from this case (Searches Documents Online, most recent documents appear on top)
> quick help with downloading > comprehensive help on Documents Online
> all documents
> Problems viewing this page? Please contact firstname.lastname@example.com giving details of the operating system and web browser you are using.


text:
Monday, 17 September 2012
TOL issued when Lynas is still scrambling to deal with its hazardous waste
statement of Save Malaysia Stop Lynas (SMSL)
TOL issued when Lynas is still
scrambling to deal with its hazardous waste
September 18th, 2012
Last Friday, a
diplomat from the Australian High Commission informed Malaysia Insider that Lynas
has applied to the regulator, the Australian Radiation Protection and Nuclear
Safety Agency (ARPANSA) to return its radioactive waste from Malaysia. According to the diplomat, Canberra has
reiterated its policy of not accepting waste from another country. This policy was also shared by the Western
Australian Government. Its Minister for
Mining and Petroleum has several times rejected in the state Parliament the
notion that Lynas can ship the waste back to WA – see relevant attached
document for details
SMSL spokesperson Mr Tan Bun
Teet responded.
"When the government approved
of the TOL for Lynas in January, no safe or viable permanent solution was found
for its waste. Today, the TOL has been issued and yet Lynas is still scrambling
around trying to find a permanent solution to its waste."
"Where is the Government's duty
of care to protect citizens and our country's future? The government is making
a fool of itself in the eyes of responsible governments the world over by
issuing the TOL at the expense of tax paying rakyat and our precious
environment." He added.
The story prompted WA State
Greens MP Robin Chapple to criticise Lynas for trying to operate outside the
law in Australia as it is operating in Malaysia where legal scrutiny on toxic
waste is not as tight as in Australia – see details in http://robinchapple.com/lynas- left-holding-baby
Rare earth refinery produces
huge amounts of waste in all streams – potentially polluting the air, the water
and surrounding land.
"We are shamed of the BN
Government for not exercising prudence when dealing with one of the world's largest
rare earth refinery project." Lamented Haji Ismail Abu Bakar, a Kuantan
resident and a SMSL spokesperson.
"It is even more embarrassing
when the Government went so far as to give Lynas a 12-year tax holiday when
ordinary Malaysian tax payers have toil and work hard to pay their taxes hoping
to live in a clean and safe country in return!" He added.
Earlier this month, the Atomic
Energy Licensing Board (AELB) claimed in its press statement on its decision to
issue the TOL that Lynas has fulfilled all of the technical and additional conditions
set by the Government and that Lynas will remove the radioactive waste. However, no detail was provided as to how
Lynas has fulfilled them for public scrutiny.
Please refer to the relevant
attached document for details of the conditions - http://on.fb.me/Rmp0tG
Ram Pususamy another Kuantan
resident retorted "show us exactly how Lynas will remove its radioactive waste
from Malaysia! Show us how Lynas has fulfilled all of the seven additional
conditions set by the AELB and MOSTI!"
When the Malaysian Government
requested the International Atomic Energy Agency (IAEA) to review the
pre-licensing stage of the Lynas project, the IAEA made eleven recommendations
which both the Malaysian Government and Lynas have publicly pledged to adhere
to - see relevant attached document for details of the recommendations - http://on.fb.me/PMBJtm
"The AELB and MOSTI think we
are fools to accept their weak and hazardous proposition when we know for a
fact that Lynas has NO way of shipping its radioactive waste OUT of Malaysia legally."
Continued Ram.
Apart from Australia's refusal
to take back Lynas' hazardous waste, trans-boundary transportation of hazardous
waste is controlled by the Basel Convention http://www.basel.int/.
Additionally, there remains
pollution risks for the air and water as huge amount of discharges in these two
streams are also expected from the Lynas plant.
In the USA at the Molycorp rare earth plant and in Lynas' Australian
licensing conditions, the company is bound to a zero-discharge condition to
prevent contamination of ground water.
In both cases, strict air pollution control of hazardous gases is
required whereas for the Malaysian plant, details of how such pollution will be
minimised remain unclear.
Furthermore, the AELB's track
record in managing radioactive waste remains poor and unsatisfactory. It has failed
to recover all of the radioactive waste from the previous rare earth plant in
Bukit Merah as would be expected under international standards to ensure public
"With the strong public support
we will do whatever it takes here in Malaysia, in Australia and in every corner
of the world where Lynas hopes to conduct its business. We will pursue legal actions and a wide range
of campaigning activities with the support of our allies until the rare earth
plant is shut down." Concluded Mr Tan.
radioactive Waste
2 comments:
After reading this post/posts I can not help but point out factual evidence that is lacking in your argument. After reading this it appears that the main concern is no longer whether correct procedures are being met but, that everyone wants Lynas Corporation out of the country? To set up and run any business you need to meet strict regulations and a project of this magnitude would need exactly those before it could even be built.A great county such as Malaysia would surely have these correct guidelines in which to follow which no doubt have been meet. To spread incorrect information and encourage such behavior is not right.
Subscribe to:
Post Comments (Atom)


text:
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The main aim of the study is to investigate the combined effects of using anabolic steroids and protease inhibitors on fat metabolism and body composition of People Living with HIV/AIDS.
We are seeking to answer the following questions:
1) Are there any significant differences in serum blood lipids, lipodystrophy, in persons with HIV taking antiretroviral therapies and anabolic steroids versus antiretroviral therapies alone?
Condition | Intervention |
HIV AIDS Lipodystrophy Hyperlipidemia |
Procedure: testosterone injection |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
Official Title: | The Effects of Anabolic Steroids and Protease Inhibitors on Serum Blood Lipids,Muscle Mass, and Total Body Fat in People Living With HIV/AIDS |
- differences in serum lipid levels
- differences in regional and overall body fat level
- impacts on metabolic and cardiovascular health
- quantity of muscle tissue between group comparison
- comparison of 3 determinants of body composition(MRI,skinfold,BIA)
Estimated Enrollment: | 30 |
Study Start Date: | September 1999 |
Estimated Study Completion Date: | June 2001 |
Changes in body composition and wasting have been a constant concern for people living with HIV/AIDS. Testosterone and its derivatives, anabolic steroids (AS) are being used by persons with HIV/AIDS (PHA's) to treat AIDs related wasting syndrome and also for bodybuilding purposes. some studies have shown that AS had a positive impact on the weight and well-being of HIV seropositive individuals.
It has been shown that protease inhibitors (PI's) in combination with other antiretroviral HIV therapies are associated with a symmetrical loss of subcutaneous fat from the body surface (lipodystrophy)in some PHAs.
The mechanism for lipodystrophy is not well understood. However, it is associated with hyperlipidemia that contributes to central fat deposition, insulin resistance, and in some, type 2 diabetes. As well, increased visceral abdominal fat and loss of fat inthe arms, legs and face, and increased levels of serum lipids have been reported.The health effects of anabolic steroid therapy coupled with PIs has not been examined before.
This study is an observational study investigating the phenomenon of lipodystrophy in an HIV population already exposed to AS and PIs. A prospective observational design will be employed, with two groups recruited. One group will be taking AS and PI's, the other will be taking PIs only.
The groups will be asked to completed Quality of Life nutrition and physical activity questionnaires. Serum blood lipid characteristics will be compared, and body composition will be determined using MRIs, BIA's and skinfold measurements.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- documented HIV seropositive status
- 18 years of age or older
- combination antiretroviral therapies for at least three months or more
- able to comply with study procedures and protocol
- signed informed consent
Exclusion Criteria:
- acute opportunistic infections at baseline
- use of serum lipid lowering drugs
- use of serum sugar controlling drugs
- evidence of drug or alcohol use which may interfere with study participation
- a recent illness with associate weight loss of greater than or equal to 10lbs
Please refer to this study by its ClinicalTrials.gov identifier: NCT00202241
Canada, Ontario | |
Queen's University | |
Kingston, Ontario, Canada, K7L 3N6 |
Principal Investigator: | Wendy Wobeser, MD | Queen's University |
Responsible Party: | Dr. Wendy Wobeser, Principal Investigator, Queen's University |
ClinicalTrials.gov Identifier: | NCT00202241 History of Changes |
Other Study ID Numbers: |
Study First Received: | September 13, 2005 |
Last Updated: | January 12, 2016 |
Keywords provided by Queen's University:
HIV AIDS testosterone anabolic steroid body composition |
lipodystrophy MRI BIA skinfold measurements protease inhibitors |
Additional relevant MeSH terms:
Hyperlipidemias Lipodystrophy Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Skin Diseases, Metabolic Skin Diseases Testosterone Testosterone enanthate Testosterone undecanoate Testosterone 17 beta-cypionate Methyltestosterone Protease Inhibitors HIV Protease Inhibitors |
Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Anabolic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on March 28, 2017


text: Your Morning After Super Bowl Cardinals-Were-Hosed PostRick Chandler2/02/09 8:45amFiled to: super bowl xliiiKurt WarnerArizona CardinalsPittsburgh Steelers23EditPromoteShare to KinjaToggle Conversation toolsGo to permalink Not saying that the last play by Warner was or wasn't an incomplete pass, but did officials actually look at the replay? Couldn't God have thrown a red flag from the heavens? [YouTube]Reply23 repliesLeave a reply


text:
Full profile →'">
The author is a Forbes contributor. The opinions expressed are those of the writer.
Accused NSA whistleblower Edward Snowden is on the run, and the media is dutifully following with millions of us in tow. The Obama administration claims he is a traitor and is working tirelessly to color the popular narrative that Snowden's actions represent a threat to national security. Although he hasn't sold his secrets to other governments, the administration says he's guilty of espionage and plans to prosecute him to the fullest extent possible.
Others see Snowden as a conscience-driven hero who alerted us to what might be the most insidious domestic spying program to date, and sparked a long overdue discussion about the fragility of our privacy in the age of information and terrorism.
Whether you agree with the government position or think Snowden is a privacy hero, the question of what motivates someone to blow the whistle—and at such a high level—is worth asking.
Is he a "rescuer"?
According to C. Fred Alford, professor of political philosophy and author of the definitive book, "Whistleblowers", a rescuer is motivated by saving others from an imminent fate. The classic example is someone in a privileged government position who discovers plans to carry out genocide. The rescuer feels compelled to do something to prevent an occurrence that he or she knows is wrong. Most importantly, a rescuer is compelled by conscience to not be a bystander.
Genocide is an extreme example, but it frames the point that a rescuer is motivated by preventing harm from befalling others, whether it's physical or psychological harm. By this definition, is Snowden a rescuer?
Perhaps. His interviews—if taken at face value—reveal a desire to open the eyes of Americans to the fact that our government is abusing its power. By revealing the NSA's virtually unlimited ability to gather personal data on U.S. citizens, Snowden was arguably acting on behalf of unknowing victims, or at least believes he was.
Is he a narcissist?
Many have suggested that people like Snowden are motivated by the allure of international attention; that they are textbook narcissists in search of fame—be it of a positive or negative flavor.
True narcissists (by the Diagnostic Standard Manual definition) have an inflated sense of self and are convinced that the moral and ethical rules that constrain others don't apply to them, or at least not in the same way. They see themselves as the perennial exception to every rule. Fame need not be the ultimate goal of a narcissist, but drawing attention to oneself certainly is. From what we know so far of Snowden, can we conclude that he's a narcissist?
Possibly, but if we look at the consequences he's facing (even if he isn't convicted of espionage), it hardly seems that he thinks he's above the rules. His best-case scenario is that he will live out the rest of his natural life in hiding from the most powerful government on the planet, never able to step foot in the U.S. again.
Snowden revealed his secrets knowing that he would be labeled a criminal—despite the value of what he disclosed—and knew the repercussions. And we also have to remember that he was already living the good life as a well-paid professional in Hawaii. Would a true narcissist, not yet 30 years old, give up wealth and esteem to become an international fugitive?
Is he motivated by distinction?
The question of narcissism may fall short of a definitive answer, but a whistleblower doesn't have to be a narcissist to want a place in history. How many people will do, create or achieve something that influences culture in a meaningful way?


text:
Intel on Dec. 29 launched a new set of mini-sized solid-state drives for dual-drive notebooks, tablet PCs and enbedded applications that the company claims provide performance as high as its larger SSDs.
The 310 Series drives are sized at a mere 51mm-by-30mm and 5mm thick, about one-eighth the size of a current Intel 2.5-inch X25 flash SSD, yet they can hold up to 80GB of data.
The new drives contain 34-nanometer Intel NAND flash memory chips and are available in an m-SATA form factor in 40GB and 80GB capacities. The 310 Series also support SATA connectivity over a PCI Express (PCIe) mini-connector for on-board storage in single-drive netbooks, tablets or handheld devices.
Intel Director of Solid-State Products Marketing Troy Winslow told eWEEK that when paired with a high-capacity hard disk drive in a dual-drive laptop or desktop PC, the 310 SSDs markedly improve overall system speed by about 60 percent, according to benchmarks.
"These really help accelerate boot time and access to frequently used applications or files," Winslow said.
One of the first deployments for the 310 Series SSDs is by DRS Technologies for a new ARMOR communications tablet PC to be launched at Storage Visions in Las Vegas next month. Storage Visions is held concurrent to the Consumer Electronics Show 2010.
The ARMOR mobile and field unit tablet PC is certified to work in extreme temperatures and hold up to shock, vibration and drops, delivering up to nine hours of operating time.
The Intel SSD 310 drives are now shipping and priced at $99 for the 40GB capacity and $179 for the 80GB version, both in 1,000-unit quantities.
Intel Unveils New Line of Mini-SSDs for Laptops, Tablets
The 310 Series drives are about one-eighth the size of a standard Intel X25 NAND flash SSD, yet they can hold up to 80GB of data.


text:
Chief engineer's log, Enterprise (NX-01)
42,334pages on
this wiki
Add New Page
this wiki
At least two log entries were made in the chief engineer's log aboard Enterprise NX-01. It was recorded by Commander Tucker. (ENT: "Dawn")
Entries Edit
2152 Edit
- "Chief Engineer's Log, supplemental. For the record, I was attacked by a small craft. I don't know what I did to provoke them. Then something in this moon's atmosphere neutralized my engines and I was forced to make an emergency landing."
- "Chief Engineer's Log, supplemental. It's been two hours since we started signaling the Enterprise. No response yet. The sun's not even up yet and it's already hotter than hell. My sparring partner doesn't look too good. I can't be sure, but I don't think his species can sweat. For the record, I have learned one thing about him, his name's Zho'Kaan. Anything you want to say to the folks back home?"
- "Nohkto"
- "Yeah. That means "bad." You would be proud of me, Hoshi. I've picked up about a dozen words in his language. A couple of them are real tongue-twisters."
Starlogs of Enterprise NX-01 |
Ship's starlog |
Captain's starlogs: 2151 • 2152 • 2153 • 2154 • 2155 |
Department starlogs: Chief engineer's log • First officer's log • Chief medical officer's log • Science officer's log |
Personal logs: Captain's personal log • Jonathan Archer • Malcolm Reed |


text:
Re: mathematica and image... help me please
Zero-0_0 <zero at zero.it> writes: >i can found the free add-ons for: >1. take an image i do a array ) imagge partition) What file format for the image? ..BMP? What version of Mathematica? Perhaps I can help with that, please send me email. Thank you dont at agora.rdrop.com